Phase 2
Completed N=99
Fungal Prophylaxis With Isavuconazole for Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (HCT)
Hematologic Malignancy · Myeloproliferative Disorder
Source: ClinicalTrials.gov NCT03149055 ↗
Enrolled (actual)
99
Serious AEs
0.0%
Results posted
Aug 2020
Primary outcomePrimary: Clinical Failure of Isavuconazole Prophylaxis by Week + 14 Post Hematopoietic Stem Cell Transplant (HCT) — 81; 3; 7; 4 Participants
Summary
The purpose of this study is to study the effects of isavuconazole in preventing fungal infections in patients who have had a hematopoietic stem cell transplant (HCT).
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Clinical Failure of Isavuconazole Prophylaxis by Week + 14 Post Hematopoietic Stem Cell Transplant (HCT) |
81; 3; 7; 4 | — |
| PRIMARY Clinical Failure of Isavuconazole Prophylaxis by Week + 26 Post Hematopoietic Stem Cell Transplant (HCT) |
89; 6 | — |
Eligibility Criteria
Inclusion Criteria
- Subjects of greater than or equal to 18 years of age of either sex and of any race.
- Have received first peripheral blood, marrow or cord blood transplant from a family or unrelated donor for hematologic malignancy or myeloproliferative disorder.
Exclusion Criteria
- Proven or probable aspergillosis or other mold infection or deep mycoses including hepatosplenic candidiasis less than 60 days from first dose of ISA.
- History of allergy or intolerance to ISA.
- Clinically significant elevation of liver function tests prior to the first day of dosing (FDD) that at the discretion of the treating physician would preclude the administration of an azole antifungal.
- Familial short QT syndrome.
Data sourced from ClinicalTrials.gov (NCT03149055). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.